LLY Stock Recent News

Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead of the drugmaker's second-quarter earnings due on August 7, citing durable growth prospects and strong positioning in the obesity and diabetes markets. The bank made only minor adjustments to its revenue and earnings estimates through 2026, driven primarily by higher sales expectations for weight-loss drug Zepbound.

Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous type of brain swelling, the company said on Wednesday.

The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS , July 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Kisunla (donanemab-azbt), Lilly's once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people in the mild dementia stage of AD, with confirmed amyloid pathology.1,2  In the TRAILBLAZER-ALZ 6 study, the modified titration schedule significantly lowered the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) versus the original dosing schedule at 24 and 52 weeks, while still achieving similar levels of amyloid plaque removal and P-tau217 reduction. "We ar

As we enter a new earnings season, there are several reasons for optimism about the economy. However, potential headwinds remain, causing some investors to focus on what could happen rather than what will or won't happen.

President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon."  But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.

When you think of a great dividend stock to own, you're probably thinking of one that yields a high rate of return. But focusing on yield alone can be a mistake.

Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for market share, data from research firm Pharmarack showed on Monday.

Don't let the summer heat keep you from making money. July is a great time to invest in the stocks of top-tier companies.

Though you may think "tech stocks" when someone mentions growth, you actually can find growth stocks throughout a wide variety of industries. Even those like pharmaceuticals, often known for the steadiness of their earnings, may, through certain specialty areas, offer you the opportunity for explosive growth.